Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax

Simply Wall St.2025-12-21

Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593312020?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-21 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593312020","market":"sg","top_or_hot":-1,"title":"Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax","media":"Simply Wall St.","content":"<div>\n<p>Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-21 20:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash","article_id":"2593312020","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-after-new-ash","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593312020","pubTimestamp":1766319425,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the story behind the stock.\nSee our latest analysis for Ascentage Pharma Group International.\nThe latest ASH data land after a bumpy stretch, with a 30 day share price return of minus 11.8 percent and a 90 day share price return of minus 25.1 percent. However, a much stronger year to date share price...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06855":"亚盛医药-B","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4109":"特种化学制品","ASH":"Ashland","BK1161":"生物科技"},"translate_title":"根据Olverembatinib和Lisaftoclax的新ASH 2025血液学数据评估亚盛医药（SEHK：6855）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9,"ASH":1.5},"content_text":"Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the story behind the stock. See our latest analysis for Ascentage Pharma Group International. The latest ASH data land after a bumpy stretch, with a 30 day share price return of minus 11.8 percent and a 90 day share price return of minus 25.1 percent. However, a much stronger year to date share price return and robust multiyear total shareholder returns suggest longer term momentum is still intact rather than fading. If Ascentage’s hematology pipeline has caught your eye, this could be a good moment to see what else is shaping the sector through healthcare stocks. With the shares still trading at a steep discount to analyst estimates despite double digit revenue growth, investors now have to ask: is Ascentage an underappreciated growth story, or is the market already pricing in the next leg of upside? Most Popular Narrative Narrative: 39.3% Undervalued With Ascentage Pharma Group International last closing at HK$56.35 against a narrative fair value of HK$92.81, the valuation gap hinges on aggressive growth and margin shifts.  Analysts expect earnings to reach CN¥50.7 million (and earnings per share of CN¥0.12) by about August 2028, up from CN¥-405.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CN¥905 million in earnings, and the most bearish expecting CN¥-528.9 million.  Read the complete narrative. Want to see what kind of revenue surge, margin turnaround, and future earnings multiple are reflected in that valuation gap? The full narrative sets out the projections underpinning this fair value, including assumptions more commonly seen in hyper growth sectors. Curious which levers would need to perform strongly to support those numbers? Explore how this roadmap outlines a path for Ascentage from deep losses to meaningful profits. Result: Fair Value of $92.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, sustained heavy R&D spending and dependence on China-focused Olverembatinib revenues could quickly test the market’s confidence in this growth script. Find out about the key risks to this Ascentage Pharma Group International narrative. Another Angle on Valuation While the narrative fair value points to upside, our SWS DCF model actually suggests Ascentage Pharma Group International is trading above intrinsic value, at around HK$26.11 versus the current HK$56.35. If cash flows do not ramp as hoped, is today’s price already baking in too much optimism? Look into how the SWS DCF model arrives at its fair value. 6855 Discounted Cash Flow as at Dec 2025 Build Your Own Ascentage Pharma Group International Narrative If you see the story differently or want to dig into the numbers yourself, you can build a personalized view in minutes: Do it your way. A great starting point for your Ascentage Pharma Group International research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Act now and put Simply Wall Street’s screener to work so you do not miss compelling opportunities across different themes, growth profiles, and income strategies.  Capture potential breakout names by scanning these 3634 penny stocks with strong financials, which combine higher risk with surprisingly resilient fundamentals. Position yourself at the heart of the automation boom through these 24 AI penny stocks that power advances in machine learning, data infrastructure, and intelligent software. Lock in steadier cash returns by reviewing these 12 dividend stocks with yields > 3% that can add reliable income alongside your growth holdings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593312020","isCrawlerRequest":true}